The Electrospinning Company is a member of the HESUB consortium, which has been awarded €5.7 million over three years by the European Union 7th framework programme to develop a single-use bioreactor for the cost-effective production of human stem cells. The project started on 1 May 2013.
In focus: Ergonomics, mobile solutions and energy management with Zenon.
This year, Bogota will host the first edition of BIOLATAM, on December 9th and 10th. This event will be held biannually, on odd years, and seeks to become the leading event in Latin America for the biotechnology sector and the promotion of business opportunities between bio-technology companies and user sectors (pharmaceutical, food, veterinarian, energy, etc.) from all over the world, whose specific interests are pointed towards Latin America.
Institutions and companies from the US, Israel, France, Portugal, Great Britain, Germany and most Latin American countries, show interest in attending the event, which aims to become the biggest to date in Latin America.
EBD Group's partneringONE® software has been chosen by the organisers of BIOLATAM as the tool for managing one-on-one meetings between companies, scientists and investors interested in Latin America's biotechnology sector. The event will be held in Bogotá on 9th and 10th December 2013.
CROMSOURCE, an international full service contract research organization (CRO), today announced the official opening of new office premises in Paris, France.
SHL Group, the world’s largest privately-owned designer, developer and manufacturer of advanced drug delivery devices, signed a second Letter of Intent (LOI) with the Taiwan Ministry of Economic Affairs to invest an additional $40 million USD in Taiwan.
Fujifilm Diosynth Biotechnologies, today, formally opened its new mammalian cell culture cGMP manufacturing facility at a ceremony performed by HRH The Duke of Gloucester KG GCVO, a member of the UK Royal Family.
The Electrospinning Company is a member of the HESUB consortium, which has been awarded €5.7million over three years by the European Union 7th framework programme to develop a single-use bioreactor for the cost-effective production of human stem cells. The project started on 1 May 2013.
The PHT Clinical Science and Consulting Team brings sponsors 75+ years of collective patient reported outcomes (PROs) experience from over 650 global clinical trials. The team is experiencing strong growth and expanding its service offerings as more pharmaceutical sponsors and CROs leverage PHT Corporation’s clinical science advice and best practices gained from 650+ eClinical studies.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.